Tectonic Therapeutic Completes Key Clinical Trial Milestones
Tectonic Therapeutic (NASDAQ:TECX) reported significant progress in its clinical trials during the second quarter of 2026. The company completed enrollment for its Phase 2 APEX trial of TX45, which is being tested as a treatment for pulmonary hypertension linked to heart failure with preserved ejection fraction. An independent data monitoring committee reviewed safety and efficacy data from approximately 80% of the expected patient exposure and recommended continuing the trial without changes. The second program, involving TX2100 for hereditary hemorrhagic telangiectasia (HHT), also advanced rapidly. Tectonic completed dosing in all six single-dose cohorts of healthy volunteers as part of a Phase 1a trial. Topline results are expected by the end of Q3 2026, with plans to move into further trials if safety and pharmacokinetic data support it. Despite these clinical successes, Tectonic's net loss widened in the second quarter due to increased R&D and G&A expenses. The company ended June 2026 with $227.1 million in cash, down from $236.9 million three months earlier, but still sufficient to fund operations through early 2029.
Tickers: $TECX
Topics: biotechnology clinical trials pharma